ANK-201 / Ankyra Therap - LARVOL DELTA

Alum-anchored CD40 antibody drug conjugate (ANK-201) promotes local anti-tumor immunity and therapeutic activity without systemic toxicity in preclinical tumor models (SITC 2025) - "ANK-201 was associated with enhanced CD40 signaling in vitro, generation of anti-tumor immunity, and an improved therapeutic window. These findings validate alum anchoring as a novel delivery strategy and position ANK-201 as a promising candidate for clinical translation."

Preclinical • Oncology • CD40 • FAM20C

Ankyra Announces Publication of Phase 1 Clinical Data, and Will Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (Businesswire) - "The company has an emerging pipeline and will be presenting initial data with their ANK-201 at the Society for Immunotherapy of Cancer annual meeting on November 7, 2025...Exploratory analysis of phase 1 solid tumor patients treated demonstrates baseline levels of circulating natural killer T (NKT) cells may serve as predictive biomarkers of response to anchored IL-12 treatment...Results from an ongoing collaboration with the National Cancer Institute Center for Immuno-Oncology will report on anchored murine IL-12 in combination with a histone deacetylase (HDAC) inhibitor in checkpoint-refractory tumor models."

P1 data • Preclinical • Solid Tumor